subjects NUMBER yr age serum alpha1at levels NUMBER microm zz genotype followed NUMBER NUMBER yr spirometry measurements NUMBER NUMBER mo national heart lung blood institute registry patients severe deficiency NUMBER enrollees mortality NUMBER NUMBER ci NUMBER NUMBER multivariate analyses NUMBER NUMBER subjects contacted NUMBER mo enrolling age baseline fev1 predicted significant predictors mortality results showed subjects receiving augmentation therapy decreased mortality risk ratio rr NUMBER NUMBER ci NUMBER NUMBER NUMBER p NUMBER compared receiving therapy NUMBER subjects fev1 measurements NUMBER yr apart mean fev1 decline NUMBER rapid decline males aged NUMBER NUMBER yr current smokers fev1 NUMBER NUMBER predicted bronchodilator response subjects fev1 decline different groups p NUMBER subjects mean fev1 NUMBER NUMBER predicted fev1 decline significantly slower subjects receiving receiving augmentation therapy mean difference NUMBER NUMBER ci NUMBER NUMBER p NUMBER randomized trial exclude possibility differences factors control alpha1 antitrypsin alpha NUMBER antitrypsin NUMBER yr augmentation therapy ml yr ml yr ml yr